Pharmacokinetics of pertuzumab biosimilar compared with the original drug in cynomolgus monkeys
- Authors: Podolyakina A.I.1, Dmitrieva A.A.1, Postnikova V.A.2, Konstantinova A.A.2, Petkova A.V.1, Trashkov A.P.3, Shamsutdinova O.A.3, Terenteva D.A.1, Dubatovka E.1, Shipaeva E.V.1, Filon O.V.1, Samsonov M.Y.1, Ignatiev V.G.1
-
Affiliations:
- Joint-Stock Company "R-Pharm"
- Limited Liability Company "Research Lab"
- Kurchatov Institute
- Issue: Vol 29, No 3 (2024)
- Pages: 160-170
- Section: Original Study Articles
- Submitted: 27.09.2024
- Accepted: 05.12.2024
- Published: 21.12.2024
- URL: https://rjonco.com/1028-9984/article/view/636526
- DOI: https://doi.org/10.17816/onco636526
- ID: 636526
Cite item
Abstract
BACKGROUND: Developing biosimilar monoclonal antibodies for treating malignant diseases is a critical task. RPH-051 (pertuzumab) is a biosimilar drug, a recombinant humanized monoclonal antibody targeting type 2 human epidermal growth factor receptors. At the stage of non-clinical development, studies of pharmacokinetics of biosimilar vs. original drug product in a relevant animal species, provide important information on the comparability of drugs.
AIM: To evaluate the pharmacokinetics of the biosimilar product RPH-051 in comparison with the original drug after a single intravenous injection in a cynomolgus monkey model.
MATERIALS AND METHODS: The study was conducted in 8 cynomolgus monkeys (Macaca fascicularis) divided into 2 groups, each including 2 females and 2 males. The first group received the biosimilar RPH-051 (international nonproprietary name is pertuzumab, AO R-Pharm, Russia), the second group was treated with the comparator Perjeta® (international nonproprietary name is pertuzumab). The drugs were administered as a single intravenous dose of 50 mg/kg. Blood samples were collected before dosing, then at 1 min, 1, 2, 4, 8, 24 h, and on days 3, 7, 10, 14, 21 and 28 post-dosing. Quantitative analysis of pertuzumab serum levels was performed using enzyme-linked immunosorbent assay (ELISA) with spectrophotometric detection in the visible range of the spectrum.
RESULTS: The method of quantitative assessment of serum level of pertuzumab using (ELISA) in cynomolgus monkeys was developed. The method was validated against the following parameters: selectivity, minimum required dilution, lower limit of quantification, calibration range, accuracy and precision (within the analytical run and between runs), specificity, linearity (possibility) of sample dilution, parallelism, and stability of the analyte in serum.
Comparability of the drugs in the main pharmacokinetic parameters was established. The mean Cmax and AUClast values of RPH-051 and of the comparator were 1684.34 and 1405.34 μg/mL (Cmax); 265,282.18 and 280,168.92 (μg/mL)×h (AUClast), respectively.
CONCLUSION: Comparability between the pharmacokinetic profiles of the biosimilar RPH-051 and the originator’s drug was demonstrated. In the course of the study, no adverse clinical events, animal body weight changes, or injection site reactions associated with the tested drugs were observed.
Full Text

About the authors
Anna I. Podolyakina
Joint-Stock Company "R-Pharm"
Author for correspondence.
Email: podolyakina@rpharm.ru
ORCID iD: 0009-0002-5602-7926
Russian Federation, Moscow
Anastasia A. Dmitrieva
Joint-Stock Company "R-Pharm"
Email: aa.dmitrieva@rpharm.ru
ORCID iD: 0000-0003-4743-6189
Russian Federation, Moscow
Victoria A. Postnikova
Limited Liability Company "Research Lab"
Email: v.postnikova@researchlab.ru
ORCID iD: 0009-0007-7505-5734
Russian Federation, Moscow
Anastasia A. Konstantinova
Limited Liability Company "Research Lab"
Email: a.konstantinova@researchlab.ru
ORCID iD: 0009-0007-7077-3630
Russian Federation, Moscow
Anna V. Petkova
Joint-Stock Company "R-Pharm"
Email: zinkovskaya@rpharm.ru
ORCID iD: 0000-0002-7028-0496
Russian Federation, Moscow
Alexander P. Trashkov
Kurchatov Institute
Email: trashkov_ap@nrcki.ru
ORCID iD: 0000-0002-3441-0388
SPIN-code: 4231-1258
MD, Cand. Sci. (Medicine)
Russian Federation, MoscowOlga A. Shamsutdinova
Kurchatov Institute
Email: shamsutdinova-o-a@yandex.ru
ORCID iD: 0000-0002-2742-3965
SPIN-code: 6827-2067
Cand. Sci. (Biology)
Russian Federation, MoscowDaria A. Terenteva
Joint-Stock Company "R-Pharm"
Email: da.terenteva@rpharm.ru
ORCID iD: 0009-0000-3298-4815
Russian Federation, Moscow
Elizaveta Dubatovka
Joint-Stock Company "R-Pharm"
Email: dubatovka@rpharm.ru
ORCID iD: 0009-0003-6074-5290
Russian Federation, Moscow
Elena V. Shipaeva
Joint-Stock Company "R-Pharm"
Email: shipaeva@rpharm.ru
ORCID iD: 0000-0002-5953-984X
MD, Cand. Sci. (Medicine)
Russian Federation, MoscowOlga V. Filon
Joint-Stock Company "R-Pharm"
Email: ov.filon@rpharm.ru
ORCID iD: 0000-0002-8735-7429
Russian Federation, Moscow
Mikhail Yu. Samsonov
Joint-Stock Company "R-Pharm"
Email: samsonov@r-pharm.com
ORCID iD: 0000-0003-2685-1623
MD, Cand. Sci. (Medicine)
Russian Federation, MoscowVasily G. Ignatiev
Joint-Stock Company "R-Pharm"
Email: ignatiev@rpharm.ru
ORCID iD: 0000-0003-2818-6583
SPIN-code: 4991-2286
MD, Cand. Sci. (Medicine)
Russian Federation, MoscowReferences
- New Russian biosimilars and generics against cancer occupied 60% of the entire clinical research market in Russia. Scientific and Production Journal of Drug Development and Registration [Internet]. [cited 2024 Sep 17]. Available from: https://www.pharmjournal.ru/jour/announcement/view/1442.
- Giri M, Giri M, Thapa RJ, et al. Breast Cancer in Nepal: Current Status and Future Directions. Biomedical Reports. 2018; 8(4);325–329.
- Trapani D, Ginsburg O, Fadelu T. et al. Global challenges and policy solutions in breast cancer control. Cancer Treatment Reviews. 2022; 104
- Frolova MA. Neoadjuvant systemic therapy of HER2-positive breast cancer. Journal of Modern Oncology. 2015;17(4):22–25.
- Cross-Discipline team leader review; Center for Drug Evaluation and Research [Internet]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/125409Orig1s000CrossR.pdf
- Volskaya E. Biosimilars: regulations specificity. Remedium. 2011;3:10–12. Available from: https://cyberleninka.ru/article/n/biosimilyary-osobennosti-regulyatornyh-norm
- Eltcova EA, Ramenskaya GV, Smolyarchuk EA, Bushmanova AV. Biosimilars — drugs of the future. Pharmacokinetics and Pharmacodynamics. 2015;(1):12–15. EDN: UCDSXN
- Niyazov RR, Dranitsyna MA, Vasiliev AN, Gavrishina EV. Biosimilars: development and investigation using achievements in modern biotechnology. Diabetes mellitus. 2020;23(6):548–560. EDN: MSIKHJ doi: 10.14341/DM12576
- Ishii-Watabe A, Kuwabara T. Biosimilarity assessment of biosimilar therapeutic monoclonal antibodies. Drug Metabolism and Pharmacokinetics. 2019;34(1):64–70. doi: 10.1016/j.dmpk.2018.11.004
- Kwon O, Joung J, Park Y, et al. Considerations of critical quality attributes in the analytical comparability assessment of biosimilar products. Biologicals. 2017;48:101–108. doi: 10.1016/j.biologicals.2017.04.005
- Al-Sabbagh A, Olech E, McClellan JE, Kirchhoff CF. Development of biosimilars. Seminars in Arthritis Rheumatism. 2016;45(5):11–18.
- Mahmood I, Green MD. Pharmacokinetic and pharmacodynamic considerations in the development of therapeutic proteins. Clinical Pharmacokinetics. 2005;44(4):331–347. doi: 10.2165/00003088-200544040-00001
- Chapman K, Adjei A, Baldrick P, et al. Waiving in vivo studies for monoclonal antibody biosimilar development: National and global challenges. MAbs. 2016;8(3):427–435. doi: 10.1080/19420862.2016.1145331
- Webster C, Wong A, Woollett G. An Efficient Development Paradigm for Biosimilars. BioDrugs. 2019;33(6):603–611. doi: 10.1007/s40259-019-00371-4
- Van Meer PJ, Kooijman M, Van der Laan JW, et al. The value of non-human primates in the development of monoclonal antibodies. Nature Biotechnology. 2013;31(10):882–883. doi: 10.1038/nbt.2709
- Van Aerts L, De Smet K, Reichmann G, et al. Biosimilars entering the clinic without animal studies. mAbs. 2014;6(5):1155–1162. doi: 10.4161/mabs.29848
- Center for Drug Evaluation and Research. Pharmacology review(s). Perjeta (pertuzumab) [Internet]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/
- Samsonov MYu, Dmitrieva AA, Konopleva GE, et al. Nonclinical studies of biotechnology derived products – theory and practice specificity. Medical Journal of the Russian Federation. 2018;24(6):324–331. EDN: YYFOWL doi: 10.18821/0869-2106-2018-24-6-324-331
Supplementary files
